275 related articles for article (PubMed ID: 25397578)
1. PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC).
Stinton LM; Bentow C; Mahler M; Norman GL; Eksteen B; Mason AL; Kaplan GG; Lindkvist B; Hirschfield GM; Milkiewicz P; Cheung A; Janssen HL; Fritzler MJ
PLoS One; 2014; 9(11):e112877. PubMed ID: 25397578
[TBL] [Abstract][Full Text] [Related]
2. Anti-Proteinase 3 Antibodies as a Biomarker for Ulcerative Colitis and Primary Sclerosing Cholangitis in Children.
Laass MW; Ziesmann J; de Laffolie J; Röber N; Conrad K
J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):463-470. PubMed ID: 35703948
[TBL] [Abstract][Full Text] [Related]
3. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease.
Mahler M; Bogdanos DP; Pavlidis P; Fritzler MJ; Csernok E; Damoiseaux J; Bentow C; Shums Z; Forbes A; Norman GL
Clin Chim Acta; 2013 Sep; 424():267-73. PubMed ID: 23806819
[TBL] [Abstract][Full Text] [Related]
4. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK).
Lindgren S; Nilsson S; Nässberger L; Verbaan H; Wieslander J
J Gastroenterol Hepatol; 2000 Apr; 15(4):437-42. PubMed ID: 10824890
[TBL] [Abstract][Full Text] [Related]
5. Antineutrophil nuclear antibodies (ANNA) in primary biliary cirrhosis: their prevalence and antigen specificity.
Orth T; Gerken G; Meyer Zum Büschenfelde KH; Mayet WJ
Z Gastroenterol; 1997 Feb; 35(2):113-21. PubMed ID: 9066101
[TBL] [Abstract][Full Text] [Related]
6. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn's disease.
Horn MP; Peter AM; Righini Grunder F; Leichtle AB; Spalinger J; Schibli S; Sokollik C
PLoS One; 2018; 13(12):e0208974. PubMed ID: 30557305
[TBL] [Abstract][Full Text] [Related]
7. Anti-neutrophil cytoplasmic antibodies (ANCA) specific for one or several antigens: useful markers for subtypes of ulcerative colitis and associated primary sclerosing cholangitis.
Dobric S; Popovic D; Nikolic M; Andrejevic S; Spuran M; Bonaci-Nikolic B
Clin Chem Lab Med; 2011 Nov; 50(3):503-9. PubMed ID: 22107137
[TBL] [Abstract][Full Text] [Related]
8. Antineutrophil cytoplasmic antibody profiles differ according to type of primary sclerosing cholangitis and autoimmune hepatitis.
Crescente JG; Dellavance A; Diniz MA; Carrilho FJ; Andrade LEC; Cançado ELR
Clinics (Sao Paulo); 2021; 76():e2228. PubMed ID: 33567045
[TBL] [Abstract][Full Text] [Related]
9. Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis.
Hov JR; Boberg KM; Taraldsrud E; Vesterhus M; Boyadzhieva M; Solberg IC; Schrumpf E; Vatn MH; Lie BA; Molberg Ø; Karlsen TH
Liver Int; 2017 Mar; 37(3):458-465. PubMed ID: 27558072
[TBL] [Abstract][Full Text] [Related]
10. Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
Wunsch E; Norman GL; Milkiewicz M; Krawczyk M; Bentow C; Shums Z; Mahler M; Lopens S; Reinhold D; Franke A; Schramm C; Roggenbuck D; Milkiewicz P
Aliment Pharmacol Ther; 2021 Jan; 53(2):302-313. PubMed ID: 33159471
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC- and multivariate regression analysis.
Terjung B; Bogsch F; Klein R; Söhne J; Reichel C; Wasmuth JC; Beuers U; Sauerbruch T; Spengler U
Eur J Med Res; 2004 Sep; 9(9):439-48. PubMed ID: 15546809
[TBL] [Abstract][Full Text] [Related]
12. Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: a comparison of the alkaline phosphatase and immunofluorescent techniques.
Bansi DS; Bauducci M; Bergqvist A; Boberg K; Broome U; Chapman R; Fleming K; Jorgensen R; Lindor K; Rosina F; Schrumpf E
Eur J Gastroenterol Hepatol; 1997 Jun; 9(6):575-80. PubMed ID: 9222729
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease.
Xu Y; Xu F; Li W; Li M; Dong S; Zhang Y; Norman GL; Zhao Q; Liu L
Scand J Gastroenterol; 2020 Jul; 55(7):806-813. PubMed ID: 32568566
[No Abstract] [Full Text] [Related]
14. Evaluation of a multiplex flow cytometric immunoassay to detect PR3- and MPO-ANCA in active and treated vasculitis, and in inflammatory bowel disease (IBD).
Trevisin M; Pollock W; Dimech W; Savige J
J Immunol Methods; 2008 Jul; 336(2):104-12. PubMed ID: 18499121
[TBL] [Abstract][Full Text] [Related]
15. IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.
Schwarze C; Terjung B; Lilienweiss P; Beuers U; Herzog V; Sauerbruch T; Spengler U
Clin Exp Immunol; 2003 Aug; 133(2):283-9. PubMed ID: 12869036
[TBL] [Abstract][Full Text] [Related]
16. Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease.
Arias-Loste MT; Bonilla G; Moraleja I; Mahler M; Mieses MA; Castro B; Rivero M; Crespo J; López-Hoyos M
Clin Rev Allergy Immunol; 2013 Aug; 45(1):109-16. PubMed ID: 23345025
[TBL] [Abstract][Full Text] [Related]
17. Antineutrophil cytoplasmic antibodies in children with inflammatory bowel disease: prevalence and diagnostic value.
Olives JP; Breton A; Hugot JP; Oksman F; Johannet C; Ghisolfi J; Navarro J; Cézard JP
J Pediatr Gastroenterol Nutr; 1997 Aug; 25(2):142-8. PubMed ID: 9252899
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil antibodies (pANCA) in chronic liver disease and inflammatory bowel disease: do they react with different antigens?
Seibold F; Weber P; Schöning A; Mörk H; Goppel S; Scheurlen M
Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1095-100. PubMed ID: 8944372
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.
Hagen EC; Daha MR; Hermans J; Andrassy K; Csernok E; Gaskin G; Lesavre P; Lüdemann J; Rasmussen N; Sinico RA; Wiik A; van der Woude FJ
Kidney Int; 1998 Mar; 53(3):743-53. PubMed ID: 9507222
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical significance of anti-lactoferrin autoantibodies in inflammatory bowel diseases and primary sclerosing cholangitis.
Roozendaal C; Horst G; Pogány K; van Milligen de Wit AW; Kleibeuker JH; Haagsma EB; Limburg PC; Kallenberg CG
Adv Exp Med Biol; 1998; 443():313-9. PubMed ID: 9781375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
